Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Pfizer says people might start getting COVID-19 vaccines before the end of the year, according to a timeline it laid out Friday.

The state of play: By the end of October, the company said it hopes to know whether the vaccine is effective, the Wall Street Journal reports.

  • By the 3rd week of November, it hopes to know whether it's safe for distribution.
  • By late November, the company could request an emergency use authorization.

The big picture: This reduces the odds of a vaccine being approved before the election, but also works to reduce concerns about vaccines being approved for political reasons.

  • “To ensure public trust and clear up a great deal of confusion, I believe it is essential for the public to understand our estimated timelines,” CEO Mr. Albert Bourla said today.

The bottom line: "The vaccine candidate from Pfizer and BioNTech is among the most advanced in development, along with candidates from AstraZeneca PLC, Moderna Inc. and Johnson & Johnson," the Journal notes.

  • "Yet trials for AstraZeneca and J&J’s vaccines are on hold, at least in the U.S., as safety issues are probed."
  • "The studies’ pauses, combined with the timeline laid out by Pfizer, suggest the company’s shot could be one of the first, if not the first, to be sent to the U.S. Food and Drug Administration for review."

Go deeper:

  • Operation Warp Speed's Moncef Slaoui on the new vaccine timeline. Listen here.
  • Trump administration announces deal with CVS, Walgreens to give COVID-19 vaccine to seniors.

Go deeper

Updated 22 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: CDC director maintains Pfizer booster recommendation for high-risk workers — CDC director approves Pfizer boosters, adds eligibility for high-risk workers — FDA approves Pfizer boosters for high-risk individuals, people 65 and up.
  2. Health: America's mismatched COVID fears — Some experts see signs of hope as cases fall — WHO: Nearly 1 in 4 Afghan COVID hospitals shut after Taliban takeover — D.C. goes further than area counties with vaccine mandates.
  3. Politics: Bolsonaro isolating after health minister tests positive at UN summit — United Airlines says 97% of U.S. employees fully vaccinated — Mormon Church to mandate masks in temples.
  4. Education: Health care workers and teachers caught up in booster confusion — Asymptomatic Florida students exposed to COVID no longer have to quarantine — Education Department investigating Texas mask mandate ban.
  5. Variant tracker: Where different strains are spreading.
Bryan Walsh, author of Future
Jan 23, 2021 - Health

Schools face an uphill battle to reopen during the pandemic

Illustration: Aïda Amer/Axios

President Biden's plan to accelerate the reopening of K-8 schools faces major challenges from a still out-of-control pandemic and more contagious coronavirus variants.

Why it matters: The longer American kids miss in-person schooling, the further they fall behind. But the uncertain state of the science on the role young children play in the pandemic continues to complicate efforts to reopen schools.

Latest James Bond movie release delayed for third time

An advertisement poster featuring Daniel Craig in the new James Bond movie "No Time to Die" in Bangkok, Thailand. Photo: Mladen Antonov/AFP via Getty Images

The release of the latest James Bond film, "No Time to Die," has been postponed for the third time as the coronavirus pandemic continues to devastate Hollywood.

The state of play: The film's release, initially scheduled for April 2020, was first postponed to November 2020, and then to April 2021. MGM said this week that movie's global debut will now be delayed until Oct. 8.